Effect of combined treatment with recombinant interleukin-2 and allicin on pancreatic cancer
- 485 Downloads
This study aimed to evaluate the efficacy of combined treatment with recombinant interleukin-2 (rIL-2) and allicin on pancreatic cancer and explore the potential immunological mechanism. A total of 60 C57/BL6 nude mice pancreatic cancer xenograft models were randomized into four groups of 15 mice per group: control group, allicin treatment group, rIL-2 treatment group, combined treatment with allicin and rIL-2 group. Mice in each group were treated with saline, rIL-2, allicin, or combination of rIL-2 and allicin by weekly i.v injection for four weeks. After four weeks of treatment, eyeballs of the mice were extracted and blood was drawn, percentages of CD4+T, CD8+T and NK cell were analyzed by FACS, IFN-γ level was detected by ELISA. One mouse in each group was sacrificed to measure the weight and volume of the tumor and prepared to the paraffin section of tumor tissue. Apoptosis of the tumor cells was analyzed by TUNEL and FACS. Other mice continued to receive treatment, survival period were compared between each group. We observed a significant suppression of xenograft growth and a significant prolonged survival time in the combined treatment with allicin and rIL-2 group (P < 0.05). The most amount of apoptotic cells were observed in the combined therapy group (P < 0.05). The percentages of CD4+T, CD8+T and NK cell and serum IFN-γ level increased significantly in the combined treatment group compared with other groups (P < 0.05). Combined treatment with allicin and rIL-2 resulted in suppression of tumor growth and prolonged survival time possibly through activation of CD4+T, CD8+T and NK cell.
KeywordsRecombinant interleukin-2 Allicin Pancreatic cancer Combined treatment
This project is supported by Grants from the National Natural Science Foundation of China (No.30872510; 81200320; 81272534 and 81260349) the Natural Science Foundation of Hubei Province (No. 2008CDB127), and the Natural Science Foundation of Shanghai (No. 064119620 10411968400).
Conflict of interest
The authors declare that they have no conflict of interest.
All human studies have been approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. All persons gave their informed consent prior to their inclusion in the study.
- 8.Rozen P, Liphshitz I, Rosner G, Barchana M, Lachter J, Pel S, Shohat T, Santo E, Consortium IPC (2009) Pancreatic cancer in Israel: the epidemiology, possibilities of prevention, early detection and screening. Isr Med Assoc J 11(12):710–713Google Scholar
- 11.Brasiuniene B, Juozaityte E (2007) The effect of combined treatment methods on survival and toxicity in patients with pancreatic cancer. Medicina-Lithuania 43(9):716–725Google Scholar
- 12.von Bernstorff W, Voss M, Freichel S, Schmid A, Vogel I, Johnk C, Henne-Bruns D, Kremer B, Kalthoff H (2001) Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res 7(3):925s–932sGoogle Scholar
- 18.Singh SV, Powolny AA, Stan SD, Xiao D, Arlotti JA, Warin R, Hahm ER, Marynowski SW, Bommareddy A, Potter DM, Dhir R (2008) Garlic constituent diallyl trisulfide prevents development of poorly differentiated prostate cancer and pulmonary metastasis multiplicity in TRAMP mice. Cancer Res 68(22):9503–9511. doi: 10.1158/0008-5472.Can-08-1677 PubMedCrossRefGoogle Scholar
- 23.Degrate L, Nobili C, Franciosi C, Caprotti R, Brivio F, Romano F, Leone BE, Trezzi R, Uggeri F (2009) Interleukin-2 immunotherapy action on innate immunity cells in peripheral blood and tumoral tissue of pancreatic adenocarcinoma patients. Langenbecks Arch Surg 394(1):115–121. doi: 10.1007/s00423-008-0393-4 PubMedCrossRefGoogle Scholar
- 27.Tang X-l Jz-y, Cai S-y (2008) Enhanced effect of CD8+T cells activated by tumor lysate-pulsed DCs on killing autologous tumor cells. Chinese J Pathophysiol 1000–4718Google Scholar